Managing HAM/TSP with Fampridine
- M Marcio Menna-Barreto1
© Menna-Barreto; licensee BioMed Central Ltd. 2014
Published: 7 January 2014
HTLV-I and HTLV-II are endogenous and have shown high prevalence rates among blood donors (1.4%), pregnant women (1.1%), Guarani amerindians (5.8%), HIV-HTLV-I/HTLV-II coinfected patients (16.3%) and spastic paraparetic individuals (21.6%) among indivividuals living in the city of Porto Alegre, southern Brazil. Tropical spastic paraparesis/HTLV-I associated myelopathy is a immune-mediated inflammatory disease in mid-thoracic spinal cord determining a myelopathy, with spastic-ataxic gait, intestinal and micturitional disorders. No medication was proved to be a disease modifying drug, just physical therapy and symptomatic management. No antiretroviral drug could benefit the patients. Fampridine, a selective neuronal potassium channel blocker, was licenced in USA and other countries, since April 2010, for the treament of gait disorders in Multiple Sclerosis. Some clinical trials have shown some benefit in patients with other kind of spinal cord diseases. Since mid-2012 seven patients monoinfected by HTLV-I and HAM/TSP are regularly using. Six of them improved in ataxia, gait and strengh in the lower limbs. Micturictional dysfunction improved in two. This off-label observational experience offer a preliminary data for a broad discussion.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.